Mayoly Spindler steps up to European expansion

February 16, 2015 ctheodoropulos

BIO-Europe Spring® in Paris will see the emergence of a new player for licensing stepping fully onto the European landscape.

Mayoly Spindler is a French family-owned pharmaceutical and dermo-cosmetics company with global sales of over EUR 160 million, 45% of those outside France, its home market. Mayoly is present internationally through both affiliates in Russia, Algeria, Mexico, Brazil, Belgium and Spain and distributors in approximately 60 countries. Their product portfolio focus is on gastroenterology, from hospital specialty to OTC, and dermo-cosmetics sold exclusively in pharmacies and generally supported by dermatologist interaction. Mayoly’s 750 staff include 350 medical and pharmaceutical reps and 250 manufacturing specialists.

On its roadmap to become an international reference in gastroenterology, Mayoly is actively considering both organic and collaborative opportunities.

Broadening the European footprint

With a strong presence in France, Mayoly is determined to broaden its footprint in Western Europe. “Ideally we would like to work on regional cluster basis for territories such as the Nordic countries, United Kingdom and Ireland, Germany and Austria, Spain and Portugal,” said Jean-Baptiste Duval, who leads the company’s business development group. All options are on the table, from commercial partnerships through to asset deals and M&A projects, provided they fit the strategic intent.

Jean-Baptiste Duval, Mayoly-Spindler

Jean-Baptiste Duval, Mayoly Spindler

As a means of fueling its investment in growth, the company may contemplate selling non-strategic assets in the fields of ENT and Rheumatology. In 2014, Mayoly sold Nabucox, a non-steroidal anti-inflammatory for arthritis, to Expanscience, in order to purchase a profitable business base from Théa Laboratories in Spain.

The company also recently established a dermo-cosmetic headland in Brazil with its Topicrem flagship brand, and Duval said that progressively over the next two years GI products will be introduced there.

No stranger to partnering, Duval said Mayoly Spindler established with Ipsen a platform for commercialization of complementary portfolios not only in France but China and Mexico as well.

Enhancing the portfolio

“We are determined to maintain our very strong focus in well-defined indications within gastroenterology, ensuring high quality support of our target audiences from hospital specialists to physicians and pharmacists,” said Duval. “This is a highly competitive area where innovation is scarce. As a small company and a relatively new player in markets outside France, we face very famous brands and very big players— we need to outsmart them,” he said.

The company recently obtained decentralized and mutual recognition procedure (DCP/MRP) approvals for a portfolio of products across multiple European markets that it intends to out-license to partners for marketing and distribution. A further three DCP/MRP authorizations are expected this year. “We want to move forward quickly to seize these opportunities. For the UK alone we have five authorized products and are seeking a partner there,” said Duval. “We have authorizations for products in Ireland, Belgium, Germany, Italy, Portugal and Hungary and seek partners for marketing and distribution there.”

In order to further strengthen the portfolio, in-licensing of late-stage programs for GI indications is a second objective for Duval and his team during the partnering event in Paris, in order to support the company’s historical pace of releasing up to five new products each year. Duval said Mayoly Spindler seeks branded prescription drugs, niche generic products, healthcare products or medical devices for European and other international markets.

At BIO-Europe Spring where a potential partner brings forward a product for in-licensing in GI indications, “we would definitely want to meet this person. We will be looking for later stage products that have at least clinical data from Phase II, as well as products already on the market. We are not ready at this time to take on development for preclinical or even Phase I programs,” said Duval.


Related Posts

No related posts.

Previous Article
Bavarian Nordic advancing 12 candidates on two vaccine platforms
Bavarian Nordic advancing 12 candidates on two vaccine platforms

Over 20 years, Bavarian Nordic has grown to become a two-technology platform company for vaccines with a mu...

Next Article
Biotech IPO wave in Europe continues
Biotech IPO wave in Europe continues

It's time to get used to weekly IPO plans by European biotechs. In February alone, a wave of six biotech IP...